Juan-David Rueda Email & Phone Number

Gaithersburg, Md, Us

Gaithersburg, Maryland, United States

Singapore

Gaithesburg, Us

Baltimore, Maryland, United States

Baltimore

University Of Maryland

Create a framework for incorporating patient-driven value elements into economic evaluations.Elicited patient values on COPD treatments to inform discrete choice experiments.Economic and outcomes evaluation of treatment for multiple myeloma using SEER-Medicare data.Investigated methods for relative dose intensity of oral oncolytics using retrospective claims data. Conducted retrospective data analysis of Medicare claims data to evaluate the impact of formulary design on utilization of diabetes medications using CCW data.Development of microsimulation models in COPD.Create a framework for patient inclusion in the development of clinical guidelines. Development of cost analysis and budget impact on Alpha-1 Antitrypsin deficiency. Project manager for the West Baltimore Health Enterprise Zone on data collection and analysis.Development of qualitative research to assess the impact of the impact of the West Baltimore Primary Care Access Collaborative.

Bogotá D.C. Area, Colombia

Lead and supervise our consulting team through the following tasks: writing proposal, responding to inquiries, negotiating contracts, budget development, tracking grant progress and reporting. Development of pricing tools for reference pricing for pharmaceutical companies in Colombia.Development of a cost-effectiveness evaluation of the treatment of rheumatoid arthritis of patients in Colombia (Orencia, BMS).

Collegeville, Pa

Generation of health outcomes evidence using various study designs such as observational research, qualitative research, psychometrics, decision analysis and mathematical and economic modeling. Exposures to the pharmaceutical industry through cross-functional interaction with clinical, research and development, epidemiology, clinical statistics, and other groups.Forecasting of pediatric patients with primary biliary cirrhosis.Protocol development of a cost analysis of primary biliary cirrhosis.Identifying inputs for the development of a value proposition of a drug for the treatment of patients with primary biliary cirrhosis.Interaction and oversee the development of an economic evaluation of the treatment of patients with primary biliary cirrhosis.

Bogotá Colombia

Active member in the Acute Respiratory Infections GroupConception and development of a systemic review to assess the utility of the use of palivizumab in the treatment of preterm newborns.

Bogotá, Colombia

Research Assistant in Ministry of Health National Guidelines for “Schizophrenia”, “Growth and development” and “Dyslipidemia”.2012-2012 ConsultantConducted retrospective data analysis of the follow-up of nutritional status in 2-10 year-old children, in community-based programs that include soy-protein enriched nutrition.2010-2012 Clinical Research AssistantResearch Assistant in Ministry of Heath Guidelines of “Preterm baby”, “Congenital malformations” and “Healthy newborn”.2011-2011 ConsultantDevelopment and identification of public health interventions in risk factors of non-communicable diseases. Grant PAHO/WHO COL/LOA/1100040.001.

2011-2012 Mandatory Social Service Research ProjectLed research on Intensive Care Unit. Hyperproteic, hypocaloric, enteral nutrition in the critically ill patient: A randomized controlled clinical trial.

Cirugía General

Bogotá D.C. Area, Colombia

Development of a CEA for the treatment of MRSA using daptomycin in patients in critical care (Novartis).Development of a CEA for the treatment of MS using fingolimod (Novartis).Development of CEA for the treatment of patients with rheumatoid arthritis (Enbrel, Pfizer).Critical assessment of value propositions for pneumococcal vaccination (Pfizer). Development of a local adaptation of an economic model for the treatment of rheumatoid arthritis (tofacitinib, Pfizer).Evaluate and guide technical documents for the inclusion of Enbrel in the National Health Formulary (Pfizer).Development of an adaptation of a CEA for apixaban in atrial fibrillation (BMS/Pfizer).Development of a CEA for the treatment of invasive candidiasis infection (Pfizer/BMS).Analysis of retrospective data regarding pacemaker implantation site neuralgia treatment (Grunenthal). Development of an economic evaluation comparing kidney transplantation and renal dialysis in Colombia (Pfizer).Development of a budget impact model for the treatment with belatacept after kidney transplantation (BMS).Development of a budget impact model and CEA for the treatment of benign prostatic hyperplasia (GSK).Conducted prospective data analysis on the treatment of hypertension in Colombia (Boehringer Ingelheim). Development of a CEA and BIM in Colombia of thrombolysis for ST-segment elevation acute myocardial infarction (Boehringer Ingelheim).Characterization of the economic burden for patients with mucopolysaccharidosis VI (Biomarin). Development of a CEA for the treatment of advanced melanoma (Roche).Adaptation of CEA of dabigatran compared with warfarin, apixaban, rivaroxaban and low molecular weight heparins for the treatment and secondary prevention of venous thromboembolism in Colombia (Boehringer Ingelheim).Development of a CEA of immunosuppressive therapies in renal transplantation (Jansen).Development of a CEA for the use of premix drugs in patients in critical care (Baxter).

Boston, Ma

Center for Multicultural Mental Health Research.Led statistical analysis and manuscript development for studies related to mental health disparities and psychotropic medication utilization in the U.S.Conducted retrospective spatial data analysis of racial disparities and the use of psychotropic medication in youths in the U.S.Development of a microsimulation model to capture treatment disparities of the use of psychotropic medications and the risk of cardiovascular disease.

Bogotá D.C., Colombia

Health economics and market access consultant in HIV, rheumatoid arthritis and prostatic cancer. Development of cost-effectiveness analysis using for Zytiga, Remicade, and Prezista.Planning and development of value propositions for Zytiga, Invega, Remicade, and Prezista.International speaker for darunavir and telaprevir.

Led the development of economic models, budget impact models, risk adjustment models, and reference pricing assessments for multiple pharmaceutical companies.

Bogotá D.C. Area, Colombia

Conducted retrospective data analysis to identify the direct cost of pneumonia, meningitis and septicemia due to S. pneumoniae in three hospitals in Bogota, Colombia.

CO/CNT/1200383.001. Development of three policy briefs in tobacco control, water fluoridation, and strategies to control obesity in childhood.

Duitama, Colombia

Master Of Science (Ms), Epidemiología

Doctor Of Philosophy (Phd), Pharmaceutical Health Services Research Program, Concentration Pharmacoeconomics, Advisor: Daniel Mullins, Phd And Julia Slejko, Phd

Master Of Science - Ms, Pharmaceutical Health Services Research

Doctor Of Medicine - Md